DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:DXCM
CUSIP25213110
Phone858-200-0200
Debt
Debt-to-Equity Ratio0.79
Current Ratio5.83
Quick Ratio5.42
Price-To-Earnings
Trailing P/E Ratio-176.26
Forward P/E Ratio-196.60
P/E GrowthN/A
Sales & Book Value
Annual Sales$718.50 million
Price / Sales12.53
Cash FlowN/A
Price / CashN/A
Book Value$4.83 per share
Price / Book21.17
Profitability
EPS (Most Recent Fiscal Year)($0.58)
Net Income$-50,200,000.00
Net Margins-4.30%
Return on Equity-9.32%
Return on Assets-4.28%
Miscellaneous
Employees2,990
Outstanding Shares88,080,000
Market Cap$9,032.23
DexCom (NASDAQ:DXCM) Frequently Asked Questions
What is DexCom's stock symbol?
DexCom trades on the NASDAQ under the ticker symbol "DXCM."
How were DexCom's earnings last quarter?
DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings data on Wednesday, May, 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.32). The medical device company earned $184.40 million during the quarter, compared to the consensus estimate of $172.66 million. DexCom had a negative return on equity of 9.32% and a negative net margin of 4.30%. The business's revenue for the quarter was up 29.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.49) EPS. View DexCom's Earnings History.
When is DexCom's next earnings date?
What price target have analysts set for DXCM?
21 Wall Street analysts have issued 1-year price objectives for DexCom's stock. Their predictions range from $40.00 to $116.00. On average, they anticipate DexCom's stock price to reach $77.2059 in the next twelve months. This suggests that the stock has a possible downside of 24.5%. View Analyst Ratings for DexCom.
What is the consensus analysts' recommendation for DexCom?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 sell ratings, 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of DexCom's key competitors?
Some companies that are related to DexCom include ABIOMED (ABMD), ResMed (RMD), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Haemonetics (HAE), Globus Medical (GMED), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC) and Nevro (NVRO).
Who are DexCom's key executives?
DexCom's management team includes the folowing people:
- Mr. Terrance H. Gregg, Exec. Chairman (Age 69)
- Mr. Kevin R. Sayer, CEO, Pres & Director (Age 60)
- Mr. Quentin S. Blackford, Exec. VP & CFO (Age 39)
- Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 46)
- Mr. Andrew K. Balo, Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access (Age 70)
Has DexCom been receiving favorable news coverage?
News headlines about DXCM stock have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. DexCom earned a media sentiment score of 0.08 on Accern's scale. They also assigned headlines about the medical device company an impact score of 44.95 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are DexCom's major shareholders?
DexCom's stock is owned by many different of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (5.90%), Fred Alger Management Inc. (0.72%), Peregrine Capital Management LLC (0.33%), Chicago Capital LLC (0.27%), Bank of Montreal Can (0.04%) and Patten & Patten Inc. TN (0.03%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Eric Topol, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jonathan T Md Lord, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.
Which institutional investors are selling DexCom stock?
DXCM stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co. and Fred Alger Management Inc.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Eric Topol, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven Robert Pacelli and Terrance H Gregg. View Insider Buying and Selling for DexCom.
Which institutional investors are buying DexCom stock?
DXCM stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Bank of Montreal Can, Peregrine Capital Management LLC, State of Alaska Department of Revenue, Patten & Patten Inc. TN, Clinton Group Inc., Amalgamated Bank and Cerebellum GP LLC. View Insider Buying and Selling for DexCom.
How do I buy shares of DexCom?
Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DexCom's stock price today?
One share of DXCM stock can currently be purchased for approximately $102.23.
How big of a company is DexCom?
DexCom has a market capitalization of $9.03 billion and generates $718.50 million in revenue each year. The medical device company earns $-50,200,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. DexCom employs 2,990 workers across the globe.
How can I contact DexCom?
DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]
MarketBeat Community Rating for DexCom (NASDAQ DXCM)
MarketBeat's community ratings are surveys of what our community members think about DexCom and other stocks. Vote "Outperform" if you believe DXCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
